Results 281 to 290 of about 42,502 (303)

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

Serotonin Reuptake Inhibitors

2014
openaire   +1 more source

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Nature Reviews Clinical Oncology, 2013
Joaquin Mateo, Michael Ong, David S P Tan   +2 more
exaly  

Antidepressants: Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors

2013
openaire   +1 more source

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Nature Medicine, 2018
Yuting Sun, Jeffrey J Ackroyd, Stefan O Ciurea   +2 more
exaly  

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

Nature Reviews Cancer, 2008
Ludger Hengst, Joyce M Slingerland
exaly  

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nature Reviews Clinical Oncology, 2017
Mizuki Nishino, Hiroto Hatabu, F Stephen Hodi   +2 more
exaly  

The evolving landscape of tissue‐agnostic therapies in precision oncology

Ca-A Cancer Journal for Clinicians
Vivek Subbiah, Bettina Ryll, Razelle Kurzrock   +2 more
exaly  

Interplay between β-lactamases and new β-lactamase inhibitors

Nature Reviews Microbiology, 2019
Karen Bush, Patricia A Bradford
exaly  

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Nature, 2009
Michael A Milhollen, James J Garnsey, Lawrence R Dick   +2 more
exaly